Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease (APOSA-PAD)

This study has been completed.
Sponsor:
Collaborators:
NHS Tayside
British Heart Foundation
Information provided by (Responsible Party):
Alan Robertson, University of Dundee
ClinicalTrials.gov Identifier:
NCT01147705
First received: June 18, 2010
Last updated: July 3, 2013
Last verified: July 2013
  Purpose

Peripheral arterial disease (PAD) is a common condition that arises due to the build up of atheroma in the arteries supplying blood to the peripheral muscles and other tissues. This imbalance between oxygen supply and demand becomes particularly apparent when patients with the condition are walking. The pain and weakness they experience (mainly in the calf but less commonly in the thigh) is known as intermittent claudication and resolves upon cessation of exercise.

It is an important disease to study as it is (i) common (est. prevalence of symptomatic intermittent claudication in Scotland of 4.5%) and (ii) those with it have a 1.6 times higher relative risk of ischaemic heart disease. These patients also have a significantly higher mortality than age-matched controls at around 12% per year.

There are two main aims of therapy - (i) to reduce the risk of cardiovascular events by way of standard secondary prevention measures (smoking cessation, anti-platelet, anti-hypertensive and cholesterol-lowering therapy, diabetic control) and (ii) to treat symptoms.

Supervised exercise therapy has been shown to be beneficial in improving walking time and distance in selected patients with leg pain from intermittent claudication with an overall increase in walking distance of approximately 150 metres at three months.

There are numerous drug treatments available for consideration in PAD patients (mainly cilostazol in the UK), but many of these have either undesirable side effects or no clear evidence of benefit. The range of increase in walking distance on cilostazol was reported to be a 50-76% increase over three months compared to 20% with placebo with some significant improvements in Quality of Life (QOL) indicators, although with a significant number of adverse effects (16% vs 8% on placebo) limiting therapy. The current cost (March 2010) is £35.31/month.

Other options for therapy include angioplasty and bypass surgery. At present these are only recommended for patients who fail to respond to medical therapy and have severely disabling symptoms (in the absence of significant exercise-limiting comorbidities).


Condition Intervention Phase
Peripheral Arterial Disease
Drug: Allopurinol
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease

Resource links provided by NLM:


Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • Onset of claudication pain [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    Our primary endpoint will be the distance to onset of claudication pain at 24 weeks but we will also measure total exercise distance.


Secondary Outcome Measures:
  • Quality of life [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    To see if allopurinol improves quality of life in patients with PAD.

  • Anti-oxidant effects [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    To investigate the anti-oxidant effects of allopurinol of patients with PAD.


Estimated Enrollment: 50
Study Start Date: February 2011
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Allopurinol
Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
Drug: Allopurinol
Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
Placebo Comparator: Placebo
Same number of tablets and appearance as active drug.
Drug: Placebo
Same appearance/dosing as active drug.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   35 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- stable peripheral arterial disease (demonstrated by having a reproducible pain free walking distance on 2 consecutive treadmill tests, i.e. less than 25% variance with the reason for termination of the treadmill test must be claudication pain only)

Exclusion Criteria:

  • rest pain
  • childbearing potential
  • heart failure
  • any other exercise limiting cardiac disease
  • BP > 180/100 mHg
  • eGFR < 60 ml/min
  • liver disease
  • malignancy
  • already on allopurinol or had an adverse reaction to it
  • recent marked change in symptoms or recent (in the last six months) intervention for PAD
  • receiving treatment with either 6-mercaptopurine, azathioprine, warfarin, or theophylline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01147705

Locations
United Kingdom
Ninewells Hospital
Dundee, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
NHS Tayside
British Heart Foundation
Investigators
Study Director: Allan Struthers, MD FRCP University of Dundee
Principal Investigator: Alan J Robertson, MBChB MRCP University of Dundee
  More Information

No publications provided

Responsible Party: Alan Robertson, Clinical Research Fellow, University of Dundee
ClinicalTrials.gov Identifier: NCT01147705     History of Changes
Other Study ID Numbers: 2009CV16, 2010-020662-23
Study First Received: June 18, 2010
Last Updated: July 3, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Dundee:
Peripheral arterial disease
Allopurinol

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Allopurinol
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Gout Suppressants
Antirheumatic Agents
Therapeutic Uses
Free Radical Scavengers
Antioxidants
Antimetabolites
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 26, 2014